Cargando…
Clinical presentation and management of drug-induced gingival overgrowth: A case series
BACKGROUND: We report three patients with drug-induced gingiva overgrowth (DIGO) caused by nifedipine, a calcium channel blocker, who were treated and followed up for 1–3 years. We discussed their symptoms, treatment process, treatment prognosis, and follow-up results. CASE SUMMARY: All the patients...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610926/ https://www.ncbi.nlm.nih.gov/pubmed/34877332 http://dx.doi.org/10.12998/wjcc.v9.i32.9926 |
_version_ | 1784603194489307136 |
---|---|
author | Fang, Li Tan, Bao-Chun |
author_facet | Fang, Li Tan, Bao-Chun |
author_sort | Fang, Li |
collection | PubMed |
description | BACKGROUND: We report three patients with drug-induced gingiva overgrowth (DIGO) caused by nifedipine, a calcium channel blocker, who were treated and followed up for 1–3 years. We discussed their symptoms, treatment process, treatment prognosis, and follow-up results. CASE SUMMARY: All the patients had a history of nifedipine treatment to control hypertension. Besides nifedipine, Patient 1 was prescribed immunosuppressant cyclosporine A to control nephritis, which is also implicated in GO. Thus, we assumed that a synergistic effect between the drugs contributed to the severity of Patient 1’s condition. This condition has been reported to be more pronounced in patients with periodontitis. In the course of treatment, Patients 1 and 2 did not stop or change drugs. After initial periodontal treatment, periodontal surgery, and later periodontal support and better plaque control, their gingival hyperplasia was well managed and controlled. Under the guidance of a physician, Patient 3 replaced her calcium-channel blocker drug with losartan potassium and hydrochlorothiazide tablets. She received initial treatment without surgery, obtaining a good curative effect. CONCLUSION: Patients’ compliance, self-plaque control, and professional periodontal therapy have a vital role in treating and preventing the recurrence of DIGO. |
format | Online Article Text |
id | pubmed-8610926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-86109262021-12-06 Clinical presentation and management of drug-induced gingival overgrowth: A case series Fang, Li Tan, Bao-Chun World J Clin Cases Case Report BACKGROUND: We report three patients with drug-induced gingiva overgrowth (DIGO) caused by nifedipine, a calcium channel blocker, who were treated and followed up for 1–3 years. We discussed their symptoms, treatment process, treatment prognosis, and follow-up results. CASE SUMMARY: All the patients had a history of nifedipine treatment to control hypertension. Besides nifedipine, Patient 1 was prescribed immunosuppressant cyclosporine A to control nephritis, which is also implicated in GO. Thus, we assumed that a synergistic effect between the drugs contributed to the severity of Patient 1’s condition. This condition has been reported to be more pronounced in patients with periodontitis. In the course of treatment, Patients 1 and 2 did not stop or change drugs. After initial periodontal treatment, periodontal surgery, and later periodontal support and better plaque control, their gingival hyperplasia was well managed and controlled. Under the guidance of a physician, Patient 3 replaced her calcium-channel blocker drug with losartan potassium and hydrochlorothiazide tablets. She received initial treatment without surgery, obtaining a good curative effect. CONCLUSION: Patients’ compliance, self-plaque control, and professional periodontal therapy have a vital role in treating and preventing the recurrence of DIGO. Baishideng Publishing Group Inc 2021-11-16 2021-11-16 /pmc/articles/PMC8610926/ /pubmed/34877332 http://dx.doi.org/10.12998/wjcc.v9.i32.9926 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Case Report Fang, Li Tan, Bao-Chun Clinical presentation and management of drug-induced gingival overgrowth: A case series |
title | Clinical presentation and management of drug-induced gingival overgrowth: A case series |
title_full | Clinical presentation and management of drug-induced gingival overgrowth: A case series |
title_fullStr | Clinical presentation and management of drug-induced gingival overgrowth: A case series |
title_full_unstemmed | Clinical presentation and management of drug-induced gingival overgrowth: A case series |
title_short | Clinical presentation and management of drug-induced gingival overgrowth: A case series |
title_sort | clinical presentation and management of drug-induced gingival overgrowth: a case series |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610926/ https://www.ncbi.nlm.nih.gov/pubmed/34877332 http://dx.doi.org/10.12998/wjcc.v9.i32.9926 |
work_keys_str_mv | AT fangli clinicalpresentationandmanagementofdruginducedgingivalovergrowthacaseseries AT tanbaochun clinicalpresentationandmanagementofdruginducedgingivalovergrowthacaseseries |